The vascular facet of late-onset Alzheimer's disease: an essential factor in a complex multifactorial disorder

Purpose of review This article provides a brief overview of relevant cerebrovascular mechanisms implicated in late-onset Alzheimer's disease (LOAD) development, and highlights the main reasons for incorporating novel cerebrovascular biomarkers to the models defining a multifactorial LOAD pathogenesis. We also discuss how novel brain mapping techniques and multifactorial data-driven models are having a critical role on understanding LOAD and may be particularly useful for identifying effective therapeutic agents for this disorder. Recent findings A growing body of evidence supports that LOAD is a complex disorder, causally associated to a high multiplicity of pathologic mechanisms. New experimental and neuroimaging data, in combination with the recent use of integrative multifactorial data-driven models, support the early role of vascular factors in LOAD genesis and development. Among other relevant roles, the cerebrovascular system has a key modulatory effect on prion-like propagation, deposition and toxicity (e.g. A&bgr;, tau proteins). The early signs of vascular dysregulation during LOAD progression are notable both at the microscopic and the macroscopic scales. Summary We emphasize that LOAD should be studied as a complex multifactorial disorder, not dominated by a dominant biological factor (e.g. A&bgr;), and without disregarding any relevant pathologic factor, such as vascular dysregulation. Cerebrovascular biomarkers are invaluable for defining multifactorial disease progression models as well as for evaluating the effectiveness of different therapeutic strategies.

[1]  Ping Zhou,et al.  Brain Perivascular Macrophages Initiate the Neurovascular Dysfunction of Alzheimer A&bgr; Peptides , 2017, Circulation research.

[2]  Neil P. Oxtoby,et al.  Imaging plus X: multimodal models of neurodegenerative disease , 2017, Current opinion in neurology.

[3]  Axel Montagne,et al.  Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease , 2017, Nature Reviews Neuroscience.

[4]  Alan C. Evans,et al.  Multifactorial causal model of brain (dis)organization and therapeutic intervention: Application to Alzheimer’s disease , 2017, NeuroImage.

[5]  R. Boellaard,et al.  Subtle alterations in cerebrovascular reactivity in mild cognitive impairment detected by graph theoretical analysis and not by the standard approach , 2017, NeuroImage: Clinical.

[6]  A. Rahmim,et al.  Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition , 2017, JAMA.

[7]  Julia J. Mack,et al.  Perivascular Macrophages Limit Permeability , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[8]  Norbert Schuff,et al.  Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis , 2016, Nature Communications.

[9]  The Paradox of Research on Dementia-Alzheimer's Disease. , 2016, The journal of prevention of Alzheimer's disease.

[10]  Christina E. Wierenga,et al.  The Utility of Cerebral Blood Flow as a Biomarker of Preclinical Alzheimer’s Disease , 2016, Cellular and molecular neurobiology.

[11]  Zhen Zhao,et al.  Establishment and Dysfunction of the Blood-Brain Barrier , 2015, Cell.

[12]  Gábor Székely,et al.  Reconstructing cerebrovascular networks under local physiological constraints by integer programming , 2015, Medical Image Anal..

[13]  Baptiste Lacoste,et al.  Neuronal and vascular interactions. , 2015, Annual review of neuroscience.

[14]  Sushil Kr. Sharma,et al.  Biomarkers in vascular dementia: A recent update , 2015 .

[15]  Timothy J Keyes,et al.  Structural and functional features of central nervous system lymphatics , 2015, Nature.

[16]  Jens Frahm,et al.  Inspiration Is the Major Regulator of Human CSF Flow , 2015, The Journal of Neuroscience.

[17]  C. Iadecola,et al.  Dangerous Leaks: Blood-Brain Barrier Woes in the Aging Hippocampus , 2015, Neuron.

[18]  Arthur W. Toga,et al.  Blood-Brain Barrier Breakdown in the Aging Human Hippocampus , 2015, Neuron.

[19]  C. Nicholson,et al.  Clearance systems in the brain-implications for Alzheimer disease. , 2015, Nature reviews. Neurology.

[20]  Alan C. Evans,et al.  Epidemic Spreading Model to Characterize Misfolded Proteins Propagation in Aging and Associated Neurodegenerative Disorders , 2014, PLoS Comput. Biol..

[21]  Hélène Jacqmin-Gadda,et al.  Estimating long-term multivariate progression from short-term data , 2014, Alzheimer's & Dementia.

[22]  Nick C Fox,et al.  A data-driven model of biomarker changes in sporadic Alzheimer's disease , 2014, Alzheimer's & Dementia.

[23]  Martin Hallbeck,et al.  Spreading of amyloid-β peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance , 2014, Neurobiology of Disease.

[24]  J. Keller,et al.  Differences in amyloid-β clearance across mouse and human blood–brain barrier models: Kinetic analysis and mechanistic modeling , 2014, Neuropharmacology.

[25]  Andrew R. McKinstry-Wu,et al.  Connectome: How the Brain’s Wiring Makes Us Who We Are , 2013 .

[26]  Arne Traulsen,et al.  Extrapolating Weak Selection in Evolutionary Games , 2013, PLoS Comput. Biol..

[27]  C. Iadecola,et al.  The Pathobiology of Vascular Dementia , 2013, Neuron.

[28]  J. Trojanowski,et al.  Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. , 2013, Brain : a journal of neurology.

[29]  Nick C Fox,et al.  Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration , 2013, The Lancet Neurology.

[30]  G. Landreth,et al.  Evidence for impaired amyloid β clearance in Alzheimer's disease , 2013, Alzheimer's Research & Therapy.

[31]  Martin Hallbeck,et al.  Neuron-to-Neuron Transmission of Neurodegenerative Pathology , 2013, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[32]  M. Nedergaard,et al.  Garbage Truck of the Brain , 2013, Science.

[33]  Tammie L. S. Benzinger,et al.  Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers , 2013, Science Translational Medicine.

[34]  Jean-Michel Verdier,et al.  Increased Amyloid-β Peptide-Induced Memory Deficits in Phospholipid Transfer Protein (PLTP) Gene Knockout Mice , 2013, Neuropsychopharmacology.

[35]  Richard S. Frackowiak,et al.  Generative FDG-PET and MRI Model of Aging and Disease Progression in Alzheimer's Disease , 2013, PLoS Comput. Biol..

[36]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[37]  Gretel Sanabria-Diaz,et al.  Studying the topological organization of the cerebral blood flow fluctuations in resting state , 2013, NeuroImage.

[38]  David D Shin,et al.  Interaction of age and APOE genotype on cerebral blood flow at rest. , 2013, Journal of Alzheimer's disease : JAD.

[39]  Jerry L. Prince,et al.  A computational neurodegenerative disease progression score: Method and results with the Alzheimer's disease neuroimaging initiative cohort , 2012, NeuroImage.

[40]  G. E. Vates,et al.  A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid β , 2012, Science Translational Medicine.

[41]  Björn Granseth,et al.  Spreading of Neurodegenerative Pathology via Neuron-to-Neuron Transmission of β-Amyloid , 2012, The Journal of Neuroscience.

[42]  Sébastien Ourselin,et al.  An event-based model for disease progression and its application in familial Alzheimer's disease and Huntington's disease , 2012, NeuroImage.

[43]  B. Zlokovic Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders , 2011, Nature Reviews Neuroscience.

[44]  Claudio Soto,et al.  Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. , 2011, Seminars in cell & developmental biology.

[45]  Jürgen Götz,et al.  Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease , 2011, Nature Reviews Neuroscience.

[46]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[47]  Ronald Melki,et al.  Prion-like transmission of protein aggregates in neurodegenerative diseases , 2010, Nature Reviews Molecular Cell Biology.

[48]  M. Diamond,et al.  Prion-like mechanisms in neurodegenerative diseases , 2010, Nature Reviews Neuroscience.

[49]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[50]  M. Diamond,et al.  Propagation of Tau Misfolding from the Outside to the Inside of a Cell* , 2009, Journal of Biological Chemistry.

[51]  V. Bautch,et al.  Neurovascular development , 2009, Cell adhesion & migration.

[52]  R. Deane,et al.  Clearance of amyloid-β peptide across the blood-brain barrier: Implication for therapies in Alzheimer’s disease , 2009 .

[53]  Shaomin Li,et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.

[54]  Angel Ortega,et al.  Gender and age-dependent differences in the mitochondrial apoptogenic pathway in Alzheimer's disease. , 2008, Free radical biology & medicine.

[55]  P. Thiran,et al.  Mapping Human Whole-Brain Structural Networks with Diffusion MRI , 2007, PloS one.

[56]  Lester Melie-García,et al.  Characterizing brain anatomical connections using diffusion weighted MRI and graph theory , 2007, NeuroImage.

[57]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[58]  Olaf Sporns,et al.  The Human Connectome: A Structural Description of the Human Brain , 2005, PLoS Comput. Biol..

[59]  Berislav V. Zlokovic,et al.  Neurovascular mechanisms of Alzheimer's neurodegeneration , 2005, Trends in Neurosciences.

[60]  P. Hagmann From diffusion MRI to brain connectomics , 2005 .

[61]  Adam Douglass,et al.  Mechanism of Prion Propagation: Amyloid Growth Occurs by Monomer Addition , 2004, PLoS biology.

[62]  C. Iadecola Neurovascular regulation in the normal brain and in Alzheimer's disease , 2004, Nature Reviews Neuroscience.

[63]  J. C. Torre Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics , 2004, The Lancet Neurology.

[64]  T. Saido,et al.  Reply to: 'Clearance of amyloid β-peptide from brain: transport or metabolism?' , 2000, Nature Medicine.

[65]  T. Saido,et al.  Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition , 2000, Nature Medicine.

[66]  M. Emdin,et al.  I027: Circulating levels of cardiac natriuretic peptides measured by highly sensitive and specific IRMA methods in normal subjects and in patients with heart failure , 1998 .

[67]  P. Lansbury,et al.  The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. , 1993, Biochemistry.

[68]  R. Reed,et al.  Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. , 1993, Physiological reviews.

[69]  G. Schmid-Schönbein,et al.  Microlymphatics and lymph flow. , 1990, Physiological reviews.

[70]  J. Lewis,et al.  Origins of the neurovascular bundle: interactions between developing nerves and blood vessels in embryonic chick skin. , 1989, The International journal of developmental biology.

[71]  W. H. Lewis,et al.  The development of the arm in man , 1902 .